medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2020, Number 1

<< Back Next >>

Acta Ortop Mex 2020; 34 (1)

Effectiveness of tranexamic acid for decreased allogenic blood transfusion in total hip arthroplasty

García-Dobarganes‑Barlow FE, Romo-Aguilera IJ, Negrete-Corona J, Guevara Álvarez A, Garcini-Munguía FA, Téllez-Hoyos S

Language: Spanish
References: 14
Page: 6-9
PDF size: 121.71 Kb.


ABSTRACT

Introduction: ATC can cause considerable blood loss. To reduce the need for blood transfusion, various preoperative techniques such as administration of tranexamic acid (ATX) are used. Objective: to demonstrate that the use of ATX decreases the need for allogeneic blood transfusion in patients operated on ATC. Material and methods: Prospective, observational, descriptive study, used to observe the allogeneic blood transfusion rate in patients who underwent unilateral primary ATC from May 2016 to December 2017. ATX was applied preoperatively and after 24 hours a blood count was taken and the need for blood transfusion was assessed. Results: A total of 70 patients were included in the study. The average postoperative Hb 11.7 mg/dl with a range of 9.2 to 14.9 mg/dl and an average Ht of 37.1% with a range of 30.2 to 44.2%. None of the patients required allogeneic blood transfusión. Conclusions: This study demonstrates how ATX is a transoperative strategy to reduce the need for allogeneic blood transfusion in patients undergoing primary ATC.


REFERENCES

  1. Lei Y, Huang Q, Huang Z, Xie J, Chen G, Pei F. Multiple-dose intravenous tranexamic acid further reduces hidden blood loss after total hip arthroplasty: a randomized controlled trial. J Arthroplasty. 2018; 33(9): 2940-5. Available from: https://doi.org/10.1016/j.arth.2018.04.024.

  2. Luo Z, Wang H, Wang D, Zhou K, Pei F, Zhou Z. Oral vs intravenous vs topical tranexamic acid in primary hip arthroplasty: a prospective, randomized, double-blind, controlled study. J Arthroplasty. 2018; 33(3): 786-93. Available from: https://doi.org/10.1016/j.arth.2017.09.062.

  3. Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K, et al. The efficacy of tranexamic acid in total hip arthroplasty: a network meta-analysis. J Arthroplasty. 2018; 33(10): 3083-9.e4. Available from: https://doi.org/10.1016/j.arth.2018.06.023.

  4. Churchill JL, Puca KE, Meyer ES, Carleton MC, Truchan SL, Anderson MJ. Comparison of ε-aminocaproic acid and tranexamic acid in reducing postoperative transfusions in total hip arthroplasty. J Arthroplasty. 2016; 31(12): 2795-9.e1. Available from: http://dx.doi.org/10.1016/j.arth.2016.05.011

  5. North WT, Mehran N, Davis JJ, Silverton CD, Weir RM, Laker MW. Topical vs intravenous tranexamic acid in primary total hip arthroplasty: a double-blind , randomized controlled trial. J Arthroplasty. 2016; 31(5): 1022-6. Available from: http://dx.doi.org/10.1016/j.arth.2015.11.003.

  6. Park KJ, Couch CG, Edwards PK, Siegel ER, Mears SC, Barnes CL. Tranexamic acid reduces blood transfusions in revision total hip arthroplasty. J Arthroplasty. 2016; 31(12): 2850-5.e1. Available from: http://dx.doi.org/10.1016/j.arth.2016.05.058.

  7. Demos HA, Lin ZX, Bar WR, Wilson SH, Robertson DC, Jr VDP. Process improvement project using tranexamic acid is cost-effective in reducing blood loss and transfusions after total hip and total knee arthroplasty. J Arthroplasty. 2017; 32(8): 2375-80.

  8. Wei W, Wei B. Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty. J Arthroplasty. 2014; 29(11): 2113-6. Available from: http://dx.doi.org/10.1016/j.arth.2014.07.019.

  9. Tuttle JR, Ritterman SA, Cassidy DB, Anazonwu WA, Froehlich JA, Rubin LE. Cost bene fi t analysis of topical tranexamic acid in primary total hip and knee arthroplasty. J Arthroplasty. 2014; 29(8): 1512-5. Available from: http://dx.doi.org/10.1016/j.arth.2014.01.031.

  10. Whiting DR, Duncan CM, Sierra RJ, Smith HM. Tranexamic acid bene fi ts total joint arthroplasty patients regardless of preoperative hemoglobin value. J Arthroplasty. 2015; 30(12): 2098-101. Available from: http://dx.doi.org/10.1016/j.arth.2015.05.050.

  11. Madsen R V, Nielsen CS, Kallemose T, Husted H, Troelsen A. Low risk of thromboembolic events after routine administration of tranexamic acid in hip and knee arthroplasty. J Arthroplasty. 2017; 32(4): 1298-303. Available from: http://dx.doi.org/10.1016/j.arth.2016.10.015.

  12. Trial C, Stowers MDJ, Aoina J, Vane A, Poutawera V, Hill AG, et al. Tranexamic acid in knee surgery study-a multicentered, randomized, controlled trial. J Arthroplasty. 2017; 32(11): 3379-84. Available from: https://doi.org/10.1016/j.arth.2017.05.058.

  13. Benjamin JB, Colgan KM. Are routine blood salvage/preservation measures justified in all patients undergoing primary TKA and THA? J Arthroplasty. 2015; 30(6): 955-8. Available from: http://dx.doi.org/10.1016/j.arth.2015.01.031.

  14. Rajesparan K, Biant LC, Ahmad M, Field RE. The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. J Bone Jt Surg Br. 2009; 91(6): 776-83. Available from: http://www.bjj.boneandjoint.org.uk/cgi/doi/10.1302/0301-620X.91B6.22393.




2020     |     www.medigraphic.com